Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 301–400 of 1,078

1. Combine and conquer: challenges for targeted therapy combinations in early phase trials
   Lopez, Juanita S., Banerji, Udai · 2017 · Nature Reviews Clinical Oncology
2. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
   Pollack, M.H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A.S., Ancell, K.K., Long, G.V., Menzies, A.M., Eroglu, Z. et al. · 2018 · Annals of Oncology
3. Oncotarget
   Ross-Adams, H, Ball, S, Kate Lawrenson, Halim, S, Russell, R, Clive A Wells, Strand, SH, Orntoft, TF, Larson, M, Armasu, S et al. · 2016 · Oncotarget
4. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
   Anna C. Filley, Mario A. Henriquez, Mahua Dey · 2017 · Oncotarget
5. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)
   Mitchell, Tara C., Hamid, Omid, Smith, David C., Bauer, Todd M., Wasser, Jeffrey S., Olszanski, Anthony J., Luke, Jason J., Balmanoukian, Ani S., Schmidt, Emmett V., Zhao, Yufan et al. · 2018 · Journal of Clinical Oncology
6. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy
   Jiao, Shiping, Subudhi, Sumit K., Aparicio, Ana, Ge, Zhongqi, Guan, Baoxiang, Miura, Yuji, Sharma, Padmanee · 2019 · Cell
7. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
   Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han · 2018 · Journal of Hematology & Oncology
8. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
   Bertrand, Florie, Montfort, Anne, Marcheteau, Elie, Imbert, Caroline, Gilhodes, Julia, Filleron, Thomas, Rochaix, Philippe, Andrieu-Abadie, Nathalie, Levade, Thierry, Meyer, Nicolas et al. · 2017 · Nature Communications
9. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
   Eli P. Darnell, Meghan J. Mooradian, Erez N. Baruch, Melis Yilmaz, Kerry Lynn Reynolds · 2020 · Current Oncology Reports
10. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
    Zhao, Yunlong, Lee, Calvin K., Lin, Chia-Hao, Gassen, Rodrigo B., Xu, Xiaozheng, Huang, Zhe, Xiao, Changchun, Bonorino, Cristina, Lu, Li-Fan, Bui, Jack D. et al. · 2019 · Immunity
11. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
    Karthik S. Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Karen Danoff · 2018 · CHEST Journal
12. Prospects of immune checkpoint modulators in the treatment of glioblastoma
    Matthias Preusser, Michael K. Lim, David A. Hafler, David A. Reardon, John Howard Sampson · 2015 · Nature Reviews Neurology
13. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
    Jake S. O’Donnell, Daniela Massi, Michele W.L. Teng, Mario Mandalà · 2017 · Seminars in Cancer Biology
14. Recent Advances in the Treatment of Melanoma
    Brendan D. Curti, Mark B. Faries · 2021 · New England Journal of Medicine
15. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
    Lim, Su Y., Lee, Jenny H., Gide, Tuba N., Menzies, Alexander M., Guminski, Alexander, Carlino, Matteo S., Breen, Edmond J., Yang, Jean Y.H., Ghazanfar, Shila, Kefford, Richard F. et al. · 2019 · Clinical Cancer Research
16. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    de Filette, Jeroen, Andreescu, Corina, Cools, Filip, Bravenboer, Bert, Velkeniers, Brigitte · 2019 · Hormone and Metabolic Research
17. Phenotype plasticity as enabler of melanoma progression and therapy resistance
    Arozarena, Imanol, Wellbrock, Claudia · 2019 · Nature Reviews Cancer
18. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
    Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, Takashi Ura, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Taroh Satoh, Satoru Iwasa et al. · 2017 · The Lancet Oncology
19. Emerging evidence for adapting radiotherapy to immunotherapy
    Lorenzo Galluzzi, Molykutty J. Aryankalayil, C. Norman Coleman, Silvia Chiara Formenti · 2023 · Nature Reviews Clinical Oncology
20. Combination immunotherapy: a road map
    Patrick Alexander Ott, Frank Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok · 2017 · Journal for ImmunoTherapy of Cancer
21. CIS is a potent checkpoint in NK cell–mediated tumor immunity
    Rebecca B. Delconte, Tatiana B. Kolesnik, Laura F. Dagley, Jai Rautela, Wei Shi, Eva Maria Putz, Kimberley A. Stannard, Jian‐Guo Zhang, Charis E. Teh, Matt Firth et al. · 2016 · Nature Immunology
22. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
    Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im, Patrick Alexander Ott, Sarina Anne Piha-Paul, Philippe Lucien Bedard, Jasgit C. Sachdev, Christophe Le Tourneau, Emilie M.J. van Brummelen, Andréa Varga et al. · 2018 · Clinical Cancer Research
23. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
    Jason Alan Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Samuel Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan et al. · 2022 · Journal for ImmunoTherapy of Cancer
24. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
    Teraoka, Shunsuke, Fujimoto, Daichi, Morimoto, Takeshi, Kawachi, Hayato, Ito, Munehiro, Sato, Yuki, Nagata, Kazuma, Nakagawa, Atsushi, Otsuka, Kojiro, Uehara, Keiichiro et al. · 2017 · Journal of Thoracic Oncology
25. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
    Sara Gandini, Daniela Massi, Mario Mandalà · 2016 · Critical Reviews in Oncology/Hematology
26. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
    Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim Marie Hirshfield, Sherri Damare, Katherine Lane, Levi O. Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman et al. · 2016 · Journal of Clinical Investigation
27. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
    Weiting Qin, Li-Peng Hu, Xueli Zhang, Shuheng Jiang, Jun Li, Zhigang Zhang, Xu Wang · 2019 · Frontiers in Immunology
28. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
    Yochai Wolf, Osnat Bartok, Sushant Patkar, Gitit Bar Eli, Sapir Cohen, Kevin Litchfield, Ronen Levy, Alejandro Jiménez-Sánchez, Sophie Trabish, Joo Sang Lee et al. · 2019 · Cell
29. Mechanisms regulating T-cell infiltration and activity in solid tumors
    Lanitis, E., Dangaj, D., Irving, M., Coukos, G. · 2017 · Annals of Oncology
30. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
    Ramaswamy Govindan, Aleksandra Szczęsna, Myung‐Ju Ahn, Claus-Peter Schneider, Pablo González Mella, Fabrice Barlési, Baohui Han, Doina Elena Ganea, Joachim von Pawel, Vladimir Ivanovich Vladimirov et al. · 2017 · Journal of Clinical Oncology
31. Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins
    Maomao Zhang, Julie S. Di Martino, Robert L. Bowman, Nathaniel R. Campbell, Sanjeethan C. Baksh, Theresa Simon-Vermot, Isabella S. Kim, Pearce B. Haldeman, Chandrani Mondal, Vladimir Yong-Gonzales et al. · 2018 · Cancer Discovery
32. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
    Kugel, Curtis H., Douglass, Stephen M., Webster, Marie R., Kaur, Amanpreet, Liu, Qin, Yin, Xiangfan, Weiss, Sarah A., Darvishian, Farbod, Al-Rohil, Rami N., Ndoye, Abibatou et al. · 2018 · Clinical Cancer Research
33. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
    Salem Chouaı̈b, Muhammad Zaeem Noman, Konstadinos Kosmatopoulos, Michael A. Curran · 2016 · Oncogene
34. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
    Yared Hailemichael, Daniel Hartman Johnson, Noha Abdel‐Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher, Cara Haymaker, Khalida Wani, Chantal Saberian, Dai Ogata et al. · 2022 · Cancer Cell
35. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
    Goswami, Sangeeta, Walle, Thomas, Cornish, Andrew E., Basu, Sreyashi, Anandhan, Swetha, Fernandez, Irina, Vence, Luis, Blando, Jorge, Zhao, Hao, Yadav, Shalini Singh et al. · 2020 · Nature Medicine
36. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
    Wei, Spencer C., Anang, Nana-Ama A. S., Sharma, Roshan, Andrews, Miles C., Reuben, Alexandre, Levine, Jacob H., Cogdill, Alexandria P., Mancuso, James J., Wargo, Jennifer A., Pe’er, Dana et al. · 2019 · Proceedings of the National Academy of Sciences
37. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
    Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
38. Implications of the tumor immune microenvironment for staging and therapeutics
    Janis Marie Taube, Jérôme Galon, Lynette Marie Sholl, Scott J. Rodig, Tricia R. Cottrell, Nicolás A. Giraldo, Alexander Spyridon Baras, Sanjay S. Patel, Robert A. Anders, David L. Rimm et al. · 2017 · Modern Pathology
39. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
    Maddalena Centanni, Dirk Jan A. R. Moes, Iñaki F. Trocóniz, Joseph Ciccolini, J. G. Coen van Hasselt · 2019 · Clinical Pharmacokinetics
40. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
    Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W. et al. · 2018 · Journal for ImmunoTherapy of Cancer
41. Metal Drugs and the Anticancer Immune Response
    Englinger, Bernhard, Pirker, Christine, Heffeter, Petra, Terenzi, Alessio, Kowol, Christian R., Keppler, Bernhard K., Berger, Walter · 2019 · Chemical Reviews
42. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
    Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, Maria Górska, Barbara Polityńska, Anna M. Wojtukiewicz, Marcin Moniuszko, Piotr Radziwon, Stephanie C. Tucker, Kenneth V. Honn · 2021 · Cancer and Metastasis Reviews
43. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
    Jun Min Zhou, Kathleen Margaret Mahoney, Anita Giobbie‐Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott J. Rodig, Jingjing Li, Xinqi Wu, Lisa Helene Butterfield et al. · 2017 · Cancer Immunology Research
44. Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
    Ascierto, Paolo A., Long, Georgina V., Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona et al. · 2019 · JAMA Oncology
45. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
    Lisa Helene Butterfield, Yana George Najjar · 2023 · Nature reviews. Immunology
46. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
    Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Alain P Algazi, Omid Hamid, Christopher D Lao, Stergios J Moschos, Michael B. Atkins, Karl Lewis, Michael A Postow et al. · 2021 · The Lancet Oncology
47. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
    Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ikuo Konishi · 2016 · International Journal of Clinical Oncology
48. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
    Anand Rotte, Jiangtao Jin, Vincent Lemaire · 2017 · Annals of Oncology
49. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
    Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher Andrew Barker, Joel Micah Baumgartner, Genevieve Marie Boland, Bartosz Chmielowski, Dominick J. DiMaio, Alison B. Durham, Ryan Courtney Fields et al. · 2021 · Journal of the National Comprehensive Cancer Network
50. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology Study
    Zamarin, Dmitriy, Burger, Robert A., Sill, Michael W., Powell, Daniel J., Lankes, Heather A., Feldman, Michael D., Zivanovic, Oliver, Gunderson, Camille, Ko, Emily, Mathews, Cara et al. · 2020 · Journal of Clinical Oncology
51. Cancer Cell Membrane Camouflaged Nanoparticles to Realize Starvation Therapy Together with Checkpoint Blockades for Enhancing Cancer Therapy
    Wei Xie, Wei‐Wei Deng, Minghui Zan, Lang Rao, Guang‐Tao Yu, Daoming Zhu, Wentao Wu, Bei Chen, Liwei Ji, Liben Chen et al. · 2019 · ACS Nano
52. Recent advances in targeted strategies for triple-negative breast cancer
    Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu · 2023 · Journal of Hematology & Oncology
53. Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
    Chao Wang, Wujin Sun, Grace Wright, Andrew Zhuang Wang, Zhen Gu · 2016 · Advanced Materials
54. Treatment of Advanced Melanoma in 2020 and Beyond
    Russell William Jenkins, David E. Fisher · 2020 · Journal of Investigative Dermatology
55. Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia, Alifieris, Constantinos, Trafalis, Dimitrios T. · 2019 · Pharmacology &amp; Therapeutics
56. Immunotherapy for lung cancer
    A. Kwilas Steven, Scott A. Fisher, Bruce W.S. Robinson · 2016 · Respirology
57. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
    Yanqi Ye, Jinqiang Wang, Quanyin Hu, Gabrielle M. Hochu, Hongliang Xin, Chao Wang, Zhen Gu · 2016 · ACS Nano
58. Immune checkpoint inhibitors in challenging populations
    Johnson, Douglas B., Sullivan, Ryan J., Menzies, Alexander M. · 2017 · Cancer
59. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
    Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael T. Massengill, Mengyu Xie, Chris Massengill, David R. Noyes, Gary V. Martinez, Roha Afzal et al. · 2016 · Clinical Cancer Research
60. What does PD-L1 positive or negative mean?
    Antoni Ribas, Siwen Hu‐Lieskovan · 2016 · The Journal of Experimental Medicine
61. T Cell Dysfunction in Cancer Immunity and Immunotherapy
    Anliang Xia, Yan Zhang, Xu Jiang, Tailang Yin, Xiaojie Lu · 2019 · Frontiers in Immunology
62. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
    Dalvin, Lauren A., Shields, Carol L., Orloff, Marlana, Sato, Takami, Shields, Jerry A. · 2018 · Retina
63. Development of Immunotherapy Combination Strategies in Cancer
    Timothy Anthony Yap, Eileen E. Parkes, Weiyi Peng, Justin Tyler Moyers, Michael A. Curran, Hussein A. Tawbi · 2021 · Cancer Discovery
64. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
    Mehdi Touat, Thierry Maisonobe, Samuel Knauß, Omar Ben Hadj Salem, B. Hervier, Karine Auré, Tali‐Anne Szwebel, N. Kramkimel, Claire Lethrosne, Jean-Frédéric Bruch et al. · 2018 · Neurology
65. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
    Blando, Jorge, Sharma, Anu, Higa, Maria Gisela, Zhao, Hao, Vence, Luis, Yadav, Shalini S., Kim, Jiseong, Sepulveda, Alejandro M., Sharp, Michael, Maitra, Anirban et al. · 2019 · Proceedings of the National Academy of Sciences
66. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
    Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J. et al. · 2017 · Annals of Oncology
67. Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
    Kailin Yang, Ahmed Halima, Timothy An-thy Chan · 2023 · Nature Reviews Clinical Oncology
68. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
    Jeffrey S. Weber, Geoff Gibney, Ryan Joseph Sullivan, Jeffrey Alan Sosman, Craig Lee Slingluff, Donald P. Lawrence, Theodore F. Logan, Lynn Mara Schuchter, Suresh Nair, Leslie Anne Fecher et al. · 2016 · The Lancet Oncology
69. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
    Minlin Jiang, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou · 2021 · Acta Pharmaceutica Sinica B
70. Preclinical mouse solid tumour models: status quo, challenges and perspectives
    Gengenbacher, Nicolas, Singhal, Mahak, Augustin, Hellmut G. · 2017 · Nature Reviews Cancer
71. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
    Stroud, Chipman RG, Hegde, Aparna, Cherry, Cynthia, Naqash, Abdul R, Sharma, Nitika, Addepalli, Srikala, Cherukuri, Sulochana, Parent, Teresa, Hardin, Jessica, Walker, Paul · 2019 · Journal of Oncology Pharmacy Practice
72. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
    Jessica C. Hassel, Lucie Heinzerling, Jens Aberle, Oliver Bähr, Thomas Eigentler, Marc‐Oliver Grimm, Victor Grünwald, Jan Leipe, Niels Reinmuth, Julia K. Tietze et al. · 2017 · Cancer Treatment Reviews
73. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
    Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina et al. · 2019 · Cancer
74. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
    Dong, Matthew B., Wang, Guangchuan, Chow, Ryan D., Ye, Lupeng, Zhu, Lvyun, Dai, Xiaoyun, Park, Jonathan J., Kim, Hyunu R., Errami, Youssef, Guzman, Christopher D. et al. · 2019 · Cell
75. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
    Jason Alan Chesney, Antoni Ribas, Georgina Venetia Long, John M. Kirkwood, Reinhard Dummer, Igor J. Puzanov, Christoph Höeller, Thomas Frank Gajewski, Ralf Gutzmer, Piotr Lukasz Rutkowski et al. · 2022 · Journal of Clinical Oncology
76. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
    Daniel Zingg, Natalia Arenas-Ramirez, Dilara Şahin, Rodney Alexander Rosalia, Ana T. Antunes, Jessica Häusel, Lukas Sommer, Onur Boyman · 2017 · Cell Reports
77. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
    Linda Chen, Jacqueline Douglass, Lawrence Richard Kleinberg, Xiaobu Ye, Ariel E. E. Marciscano, Patrick M. Forde, Julie Renee Brahmer, Evan J. Lipson, William Howard Sharfman, Hans J. Hammers et al. · 2017 · International Journal of Radiation Oncology*Biology*Physics
78. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    Weijie Ma, Barbara M. Gilligan, Jianda D. Yuan, Tianhong Li · 2016 · Journal of Hematology & Oncology
79. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
    Benjamin M. Larimer, Eric Paul Wehrenberg-Klee, Frank P. B. Dubois, Anila Mehta, Taylor A. Kalomeris, Keith T. Flaherty, Genevieve Marie Boland, Umar Mahmood · 2017 · Cancer Research
80. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
    Gagan K. Gupta, Amber L. Collier, Dasom Caroline Lee, Richard A. Hoefer, Vasilena P. Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston et al. · 2020 · Cancers
81. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
    Lijie Zhai, Stefani Spranger, David C. Binder, Galina Gritsina, Kristen L. Lauing, Francis Joseph Giles, Derek Alan Wainwright · 2015 · Clinical Cancer Research
82. Repurposing metformin for cancer treatment: current clinical studies
    Young Kwang Chae, Ayush Arya, Mary‐Kate Malecek, Daniel Sanghoon Shin, Benedito A. Carneiro, Sunandana Chandra, Jason Benjamin Kaplan, Aparna Kalyan, Jessica Kaplan Altman, Leonidas C. Platanias et al. · 2016 · Oncotarget
83. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
    Praveen K. Bommareddy, Anand V Patel, Saamia Hossain, Howard L. Kaufman · 2016 · American Journal of Clinical Dermatology
84. PD-L1
    Anthousa Kythreotou, Abdul Siddique, Francesco Angelo Mauri, Mark Bower, David James Pinato · 2017 · Journal of Clinical Pathology
85. Intron retention is a source of neoepitopes in cancer
    Alicia Smart, Claire A. Margolis, Harold Pimentel, Meng Xiao He, Diana Miao, Dennis O. Adeegbe, Tim Fugmann, Kwok‐Kin Wong, Eliezer M. Van Allen · 2018 · Nature Biotechnology
86. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
    Anna C. Bibby, Selina Tsim, Nikolaos I. Kanellakis, Hannah Ball, Denis Charles Talbot, Kevin G. Blyth, Nick A. Maskell, Ioannis Psallidas · 2016 · European Respiratory Review
87. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology
    Akinori Kawakami, David E. Fisher · 2017 · Laboratory Investigation
88. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
    David J. Messenheimer, Shawn M. Jensen, Michael E. Afentoulis, Keith W. Wegmann, Zipei Feng, David J. Friedman, Michael J. Gough, Walter John Urba, Bernard A. Fox · 2017 · Clinical Cancer Research
89. Genetic profiling of hepatocellular carcinoma using next-generation sequencing
    Kornelius Schulze, Jean‐Charles Nault, Augusto Villanueva · 2016 · Journal of Hepatology
90. Emerging Opportunities and Challenges in Cancer Immunotherapy
    Theresa L. Whiteside, Sandra Demaria, Maria Esperanza Rodriguez-Ruiz, Hassane M. Zarour, Ignacio Melero · 2016 · Clinical Cancer Research
91. Rationale for anti-OX40 cancer immunotherapy
    Sandrine Aspeslagh, Sophie C. Postel-Vinay, Sylvie Rusakiewicz, Jean‐Charles Soria, Laurence Zitvogel, Aurélien Marabelle · 2015 · European Journal of Cancer
92. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
    Georgina Venetia Long, Jean‐Jacques Grob, Paul Nathan, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Stephen R. Lane, Carmen Mak, Philippe Legenne, Keith T. Flaherty et al. · 2016 · The Lancet Oncology
93. Emerging targets in cancer immunotherapy
    Samantha Burugu, Amanda R. Dancsok, Torsten O. Nielsen · 2017 · Seminars in Cancer Biology
94. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
    Jenny Lee, Georgina Venetia Long, Alexander Maxwell Menzies, Serigne Lo, Alexander David Guminski, Kataraina Whitbourne, Michelle Peranec, Richard A. Scolyer, Richard F. Kefford, Helen Rizos et al. · 2018 · JAMA Oncology
95. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
    Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B. et al. · 2017 · Annals of Oncology
96. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort
    Ready, Neal E., Ott, Patrick A., Hellmann, Matthew D., Zugazagoitia, Jon, Hann, Christine L., de Braud, Filippo, Antonia, Scott J., Ascierto, Paolo A., Moreno, Victor, Atmaca, Akin et al. · 2020 · Journal of Thoracic Oncology
97. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
    Vivek Verma, Tanja Sprave, Waqar M. Haque, Charles B. Simone, Joe Yujiao Chang, James William Welsh, Charles R. Thomas · 2018 · Journal for ImmunoTherapy of Cancer
98. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
    Narikazu Boku, Min‐Hee Ryu, Ken Kato, Hyun Cheol Chung, Keiko Minashi, K.-W. Lee, H. Cho, Won Ki Kang, Yoshito Komatsu, Masahiro Tsuda et al. · 2018 · Annals of Oncology
99. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
    Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah J. Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé Beate Steen, Bogdan A. Luca et al. · 2022 · Nature Medicine
100. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
     Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Nicolas van Baren, Sophie Lucas, Pia Kvistborg, Kris Thielemans, Bart Neyns · 2016 · Journal of Clinical Oncology